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Objectives: All people with type 2 diabetes should receive dietary advice. Some 
patients may benefit from additional dietary counseling. This study used recently 
developed statistical methods to estimate the efficiency frontier for individualized 
allocation of dietary counseling services. I. e., for each level of total health care 
expenditure, we estimate the individualized allocation of services that maximizes 
clinical benefit in the population. MethOds: People newly diagnosed with type 2 
diabetes were identified retrospectively from electronic health records and classified 
as receiving vs. not receiving dietary counseling. An individualized effectiveness 
score for achievement of HbA1c < 7% with vs. without counseling was estimated 
using multivariable logistic regression. Demographics, vitals, comorbidities and 
lab values served as candidate predictors. Prediction models were validated in a 
held-out sample. The efficiency frontier was estimated as the convex hull of the 
set of HbA1c control rates and total costs achievable by allocation of dietary coun-
seling based on the effectiveness score. Results: Among 11,819 patients newly 
diagnosed with type 2 diabetes, 22% received dietary counseling and 74% achieved 
HbA1c control. Greater HbA1c, body mass index and age at the time of diagnosis 
were associated with greater effectiveness of dietary counseling. Allocation of all 
newly diagnosed diabetics to dietary counseling was estimated to increase the 
rate of HbA1c control to 80% at a cost of 56 USD per patient vs. current practice. An 
efficient allocation rule (counseling only the 55% of patients predicted to benefit 
most) achieved the same 80% control rate with an incremental cost of 6 USD per 
patient. cOnclusiOns: Retrospective analysis of real-world data identified oppor-
tunities to improve diabetes outcomes vs. current practice with minimal expense 
through individualized allocation of dietary counseling. This result warrants valida-
tion in separate data. The analytical methods warrant broader use to investigate 
efficient allocation of treatments.
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Objectives: Chronic illness is a prolonging health defect, which is causing a big 
use of financial means for its medical care. These means are not being coordinated 
and used effectively. The aim of this study was to suggest a management care 
system of the chronically ill in the Czech Republic, which should increase the 
quality of medical care and decrease the costs of it. MethOds: There was chosen 
an appropriate diagnosis and concept for the management care, which were based 
on analysis of the current state. The type 2 diabetes mellitus was chosen as an 
appropriate chronic illness and for the management care concept was chosen 
Patient-Centered Medical Home.. The randomized selection of 100 patients was 
made in ordinary diabetes ambulance. The cost of illness was counted from the 
direct costs from the perspective of the society, of the payer and of the patient. 
The cost effectiveness analysis, which was comparing a standard treatment and 
chosen concept, was based on randomized selection, studies of Patient-Centered 
Medical Home and recommended standards of professional society. There were 
also used methods of value engineering especially Saaty matrix and multi-cri-
teria decision making, mainly TOPSIS method for setting the scales of criteria 
and effect. Results: The average costs of one patient are from the perspective 
of the society 29 531 CZK, the payer 20 976 CZK and of the patient 9 196 CZK. The 
Patient–Centered Medical Home has taken the first place in comparison with a 
standard treatment, which was based on the cost of effectiveness analysis. The 
payer will obtain a 25.7x10-5 of the effect for Patient-Centered Medical Home 
according a spent monetary unit. cOnclusiOns: The costs of the chosen concept 
can be more effective. The concept would provide greater prevention, quality and 
coordinated care and can be used for other chronic diseases.
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Objectives: Sensor augmented therapy (SAP) with automated insulin suspen-
sion is the most advanced technology for the treatment of severe and moderate 
hypoglisemia in patients with type 1 diabetes mellitus. In order to sustain a bet-
ter uptake of sensor augmented therapy for patients, it is crucial for this tech-
nology to be included in the reimbursement scheme of Turkey and in the other 
countries. Thus, we aimed to study and analyze reimbursement status of this 
technology in Turkey and across other selected countries of Western Asia, North 
America and Western Pacific. MethOds: Mainly official web resources such as 
health authority web pages, direct contact with authority responsibles and pub-
lished articles on SAP are utilized. Results: Most of the countries examined 
have either reimbursement or limited status of SAP. European countries such 
as Ireland, The Netherlands, Sweden, Estonia, Czech Republic; Israel in Western 
Asia, Japan in Western Pacific and USA are the ones where this technology is reim-
bursed mainly for patients with Type 1 Diabetes. Within these selected countries, 
Turkey has a position of having reasonably well defined reimbursement status 
for SAP despite insufficient number of sensors reimbursed - 2 sensors instead 
of 5 sensors a month; which potentially causes an incomplete therapy for the 
patients. cOnclusiOns: Despite the operational hurdles and insufficient number 
of sensors reimbursed per patient in Turkey, the country still stands as a success-
ful example of reimbursement practice, by making this technology available for 
the indicated patients.
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Objectives: A pharmacy-based inpatient diabetes management program was 
evaluated to determine if improved glycemic control could be achieved in a gen-
eral medicine patient population. MethOds: A retrospective chart review of 151 
patients with blood glucose (BG) values outside the range 70-180 mg/dL was con-
ducted. Observations for the baseline group (n= 84) were derived from July 2010 and 
for the intervention group (n= 67) in October 2010. The odds of poor glycemic control 
for patients in the intervention versus baseline groups were assessed by multi-
variate generalized estimating equations. These methods were also used to assess 
patient characteristics associated with poor glycemic control. Results: Across all 
patients, no evidence was observed indicating the pharmacy program decreased the 
proportion of days spent out of the targeted blood glucose range [70-180 mg/dL: OR 
0.91 (95% CI: 0.83 – 1.02); 70-250 mg/dL: OR 1.03 (95% CI: 0.88 – 1.24)]. However, the 
subgroup of patients whose admission blood glucose was less than 200 mg/dL (55% 
of intervention group) experienced a significant reduction in days out of range for 
both ranges [70-180 mg/dL (OR: 0.72, 95% CI: 0.61– 0.88) and 70-250 mg/dL (OR: 0.5, 
95% CI: 0.33 – 0.71)]. No improvement in glycemic control was observed in patients 
with an admission BG 200 mg/dL or greater. These patients had more disease- and 
social-related factors associated with poor glycemic control. cOnclusiOns: A sub-
population, patients whose admission glucose was less than 200 mg/dL, experienced 
improvement in glycemic control in the pharmacy-based program. The remaining 
patients were generally more complicated from a disease-state and social perspec-
tive and experienced no improvement. These patients may require a more intense, 
multi-disciplinary approach that is better matched to the constellation of factors 
responsible for their condition.
PDB147
comPliaNce to hemogloBiN a1c testiNg RecommeNDatioNs folloWiNg 
iNitial DiaBetes DiagNosis
Palmer L.A.1, Hansen L.G.2
1Truven Health Analytics, Bethesda, MD, USA, 2Truven Health Analytics, Northwood, NH, USA
Objectives: The hemoglobin A1c test (HbA1c) is the favored measure of gly-
cemic control for patients with diabetes. Compliance to recommended testing 
continues to be a challenge. The current analysis evaluates how compliance to 
HbA1c testing varies based on initial HbA1c results. MethOds: Newly diagnosed 
patients with Type II diabetes were identified using the Truven Health MarketScan 
Lab Database (1/1/2010-10/31/2013). Continuous eligibility for the 6 months prior 
and 12 months following diagnosis were required for study inclusion. Patient 
cohorts were created based on first HbA1c test value (< 7.0% [controlled], ≥ 7.0% 
[uncontrolled]). Presence of a subsequent HbA1c test, including test result and 
time to test, were evaluated for these cohorts. Results: A total of 133,011 
patients met the study inclusion criteria; approximately 40% had evidence of 
an initial HbA1c test (n= 33,616 with HbA1c < 7.0%; n= 19,033 with HbA1c ≥ 7.0%). 
Approximately 64% (n= 21,497) of controlled patients had a subsequent HbA1c 
test (86% with HbA1c < 7.0%, 14% with HbA1c ≥ 7.0%); 91% (n= 17,344) of uncon-
trolled patients had a subsequent HbA1c test (36% with HbA1c < 7.0%, 64% with 
HbA1c ≥ 7.0%). Mean times (in days [d]) to subsequent HbA1c test (and result) 
were as follows: Among initially controlled patients: 231d (controlled) and 370d 
(uncontrolled); among initially uncontrolled patients: 238d (controlled) and 212d 
(uncontrolled). Mean time to HbA1c test was significantly longer for controlled 
patients with HbA1c ≥ 7.0% for subsequent test relative to controlled patients 
with HbA1c < 7.0% and to uncontrolled patients with HbA1c ≥ 7.0% for subsequent 
tests. cOnclusiOns: Compliance to recommended timing for HbA1c testing 
is suboptimal in the majority of patients regardless of initial glycemic control. 
Importance of regular HbA1c evaluation should continue to be part of patient 
education – particular for patients who may initial appear to have favorable gly-
cemic control.
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Objectives: The Syreon health economic model was developed to predict long 
term effects of screening, treatment and control of type 2 diabetes, by taking into 
account baseline patient characteristics, history of complications, changes in physi-
ological parameters, diabetes treatment and management strategies and screening 
programs. The aim of this analysis was to assess the cost-effectiveness of intro-
ducing a national public health program in Hungary to improve diabetes patient’s 
adherence in comparison to not introducing the program. MethOds: According 
to the guideline of the Hungarian National Diabetes Association, the target HbA1c 
level is below 7%, except for special cases, where it is 8% or less. Without an organ-
ized patient education program 45% of the patients with known diabetes have 
higher than the target HbA1c level. In the studied scenario, the education program 
improves the patient adherence by 30% and increases the proportion of diabetic 
patients achieving the target HbA1c level to 72%. Patients reaching the target HbA1c 
level fully enjoy the benefits of efficient treatment. Non-adherent patients have 
higher HbA1c levels and face higher risk for diabetes-related complications, e. g. 
stroke, neuropathy or retinopathy. Results: The Syreon diabetes model is capable 
of analyzing the consequences of introducing the adherence program for patients 
with diagnosed diabetes. The results of the cost-effectiveness analysis were sensi-
tive to the starting age of the target population and the effectiveness of the training 
program. cOnclusiOns: Organized patient education program was predicted to 
be cost-effective compared with no program in Hungary. The education program 
contributes to better patient adherence resulting in better health and less disease 
related complications.
